For the final biopharmaceutical product approval and subsequent manufacturing processes, a comprehensive characterization of mab purity, aggregate forms, and charge variants is required by the regulatory agency. There is a clear need to reduce costs and manufacturing risk in order to. Introduction to antibody production and purification thermo. Monoclonal antibody production a report of the committee on methods of producing monoclonal antibodies institute for laboratory animal research national research council national academy press washington, dc 1999. Simultaneous removal of leached proteina and aggregates from monoclonal antibody using hydrophobic interaction membrane chromatography. Dec 16, 2016 understanding and managing aggregates are critical to your monoclonal antibody mab process. Table 1 summarizes potential sources of aggregate formation during. Are you considering how best to manage and remove aggregates across your template. Monoclonal antibodies mab or moab are antibodies that are made by identical immune cells that are all clones of a unique parent cell. Dec 16, 2016 aggregates in monoclonal antibody manufacturing processes biotechnol bioeng 2011, 108 7, 1494508. One of these molecules was further evaluated in realistic bioreactor stress models and in cell culture fermentations. Imbaratto, cell culture manufacturing, covance biotechnology services, inc. A read is counted each time someone views a publication summary such as the title, abstract, and list of authors, clicks on a figure, or views or downloads the fulltext.
Aggregation mechanism of an igg2 and two igg1 monoclonal. Aggregation kinetics for monoclonal antibody products. The outcomes of this study will benefit scientists and engineers who develop biologic product manufacturing processes by providing a better understanding of drug product. Guideline on development, production, characterisation and. The structure of the monoclonal antibody should be justified with respect to its mechanism of action. The formation of aggregates is a common but highly undesirable occurrence during monoclonal antibody purification. Quality attributes of monoclonal antibodies and effect of cell culture. The principles described in this document apply to monoclonal antibodies used as reagents, as well as monoclonal antibody related products, such as fragments, conjugates, and fusion proteins. Taken together, these developments are driving the industry to explore alternative separation technologies as a future manufacturing strategy. For the final biopharmaceutical product approval and subsequent manufacturing processes, a comprehensive characterization of mab. Watch our experts discuss which steps in the biomanufacturing process are involved in the formation or removal of aggregates and industryleading approaches. Aggregates in the final drug product are undesirable for two major reasons. The small molecules attached to the mab are often relatively hydrophobic.
Monoclonal antibodies mabs are the fastestgrowing biological therapeutics with important applications ranging from cancers, autoimmunity diseases and metabolic disorders to emerging infectious diseases. Current trends in monoclonal antibody development and. Aggregates in monoclonal antibody manufacturing processes biotechnol bioeng 2011, 108 7, 1494508. The stability of 11 purified monoclonal human igg1 and igg4. The primary objective of this project was to use the experimental analysis together with the knowledge of chemical kinetics to build a kinetic model for protein.
Thus, values obtained from sec may not actually represent the true aggregate levels in the protein drug container, so there is a continued effort to. In the broad sense, it refers to the entire process of creating a usable specific antibody, including steps of immunogen preparation, immunization, hybridoma creation, collection, screening, isotyping, purification, and labeling for direct use in a particular method. Hic as a complementary, confirmatory tool to sec for the. Jan 09, 2018 the formation of aggregates is a common but highly undesirable occurrence during monoclonal antibody purification. Removing the aggregates of an acidic monoclonal antibody with. Upon binding, the full adc can be internalized by a process called receptormediated endocytosis. Monoclonal antibodies mabs are the fastestgrowing biological therapeutics with important applications ranging from cancers, autoimmunity diseases and metabolic disorders to.
Aggregation mechanism of an igg2 and two igg1 monoclonal antibodies at low ph. Aggregates in monoclonal antibody manufacturing processes. In this talk, herb lutz, global consultant, will discuss the formation of protein aggregates and their. For example, we have seen issues in manufacturing, such as quality, process. Clarification technologies well established in other industries, such as flocculation and precipitation are increasingly considered as a viable solution to address this bottleneck in antibody processes. Managing aggregates in your monoclonal antibody mab process. Given the high cell densities achievable in both mammalian cell culture and microbial processes, primary recovery can be a significant challenge at lab, pilot and commercial manufacturing scales. In this talk, herb lutz, global consultant, will discuss the formation of protein. Impact of media and antifoam selection on monoclonal. Usp manufacturing processes which generate higher titers still take. Largescale manufacturing of pharmaceutical antibodies.
Size exclusion chromatography analysis of antibody drug. Aggregate content of cht xt eluate mab s significant reduction of the mab s aggregate was achieved unosphere supra eluate. Trends in upstream and downstream process development. This study demonstrated the suitability of cationexchange laterallyfed membrane chromatography lfmc for rapid and highresolution separation of monoclonal antibody mab aggregates. Selecting the optimal resins for aggregate removal references he x et al. Howe ver, their applicability will be determined on a case bycase basis, based on their specific properties, and may be addressed in specific annexes. Aggregation of mabs continues to be a major problem in their developability. Secretory leakage of igg1 aggregates from recombinant.
Pdf aggregates in monoclonal antibody manufacturing processes. Stress factors in mab drug substance production processes. Secretory leakage of igg1 aggregates from recombinant chinese. Understanding and managing aggregates are critical to your monoclonal antibody mab process. The current trend for cell culture processes is to increase. Overall purification performance of cht xt chromatography is summarized in table 1. Analysis of monoclonal antibodies and their fragments by. Humanized monoclonal antibody produced by mammalian cell culture may contain significant amounts of antibody dimers and smaller amounts of higher order aggregates. Since the approval of the first therapeutic monoclonal antibody in 1986. Protein aggregation remains a major area of focus in the production of monoclonal antibodies. Processing impact on monoclonal antibody drug products. The agilent advancebio sec column, used with the agilent 1260 biolc system, proved capable of. The agilent advancebio sec column, used with the agilent 1260 biolc system, proved capable of delivering high resolution analysis of mab aggregates with short run times.
Capto adhere is a multimodal ion exchanger and is designed to be used as a second or third step in monoclonal antibody mab puri. Production processes for monoclonal antibodies intechopen. Review aggregates in monoclonal antibody manufacturing processes marava. Protein a chromatography pac is commonly used as an efficient capture step in monoclonal antibody mab separation processes. Monoclonal antibody mab products have emerged as an extremely important and valuable class of therapeutic products for the treatment of cancer and other diseases such as rheumatoid arthritis, autoinflammatory disease, allergic asthma, and multiple sclerosis 1, 2. During the manufacturing process, the protein is exposed to multiple stress. Recovery and purification process development for monoclonal. Preparative separation of monoclonal antibody aggregates. In custom antibody development, once target selection. For some years, new methodologies have advanced with new production processes, allowing scaleup production and market introduction. To investigate antibody stability and formation of modified species under upstream processing conditions. This study demonstrated the suitability of cationexchange laterallyfed membrane chromatography lfmc for rapid and highresolution separation of monoclonal antibody.
Evolution of the monoclonal antibody purification platform. Biomanufacturing of monoclonal antibodies mab involves a number of unit operations, including cell culture in a bioreactor followed by chromatography and filtration. A systematic framework to optimize and control monoclonal. Aggregates in monoclonal antibody manufacturing processes marava. Various economic analyses estimate that process development and clinical manufacturing costs can. Monoclonal antibody mab products have emerged as an extremely important and valuable class of therapeutic products for the treatment of cancer and other diseases such. Review aggregates in monoclonal antibody manufacturing processes mar. These include production cell culture, harvest, antibody capture by protein a, virus. To demonstrate the analysis of monoclonal antibody mab aggregates. Individual antibodies vary widely in their propensity to form aggregates 5.
Trends in upstream and downstream process development for. The study of aggregation propensity of a monoclonal antibody mab and its. Factors influencing biotherapeutic monoclonal antibody. Reliable, timely and costeffective monoclonal antibody production and purification programs.
Largescale production has revolutionized the market for monoclonal antibodies by boosting its production and becoming a more practical method of production. Mab aggregates may form during protein expression, downstream processing, and storage, and may be caused. Current trends in monoclonal antibody development and manufacturing will provide readers with an understanding of what is currently being done in the industry to develop, manufacture, and. Aggregates have been characterized in mab purification and formulation. Purification is intended to remove impurities, such as protein aggregates, but some such operations may actually generate protein aggregation 1.
See how oncolumn aggregation is dependent on the type of resin used and how one particular highresolution cation exchange resin allows for the lowest proportion of aggregate formation. Prediction and reduction of the aggregation of monoclonal antibodies. As a result, aggregation has to be monitored throughout process development and manufacturing of a mab product. Predicting aggregation propensity and monitoring aggregates. Review aggregates in monoclonal antibody manufacturing processes mara va. This hydrophobicity can be problematic during manufacturing and storage in terms of aggregate formation as well as in analytical characterization of the latter1. Monoclonal antibodies are expensive to develop and to manufacture. Preparative separation of monoclonal antibody aggregates by. Due to their broad application range, monoclonal antibodies mab are used worldwide in a variety. Strategies for the assessment of protein aggregates in pharmaceutical biotech product development. Removing aggregates in monoclonal antibody purification.
This 31 st article in the elements of biopharmaceutical production series focuses on evolution of the purification platform for manufacturing of mab therapeutics. Pdf monoclonal antibodies have proved to be a highly successful class of therapeutic products. Monoclonal antibodies mabs are a successful class of therapeutic products used increasingly in the past 1520 years, but the manufacture of safe and effective mab drug products provides many challenges to downstream molecule purification. The study focuses on very large scale processes in the region of five 5 tonnes per annum of bulk antibody. In the creation of this study, we used the industry standard modelling software, biosolve process, to address these questions. Monoclonal antibody production in commercial scale cell culture bioprocessing requires a thorough understanding of the engineering process and components used. The term antibody production has both general and specific meanings.
Low ph elution can induce mab aggregation in protein a chromatography 7, 8. This 31 st article in the elements of biopharmaceutical production series focuses. Here, we explore the potential of predicting and reducing the aggregation propensity of monoclonal antibodies. Antibody aggregation can occur at various stages including the up and downstream processes in manufacturing, formulation, and longterm storage 5, 6. Integrated flowthrough purification for therapeutic. Mar 25, 2018 aggregates in monoclonal antibody manufacturing processes. Jan 16, 20 to investigate antibody stability and formation of modified species under upstream processing conditions. Size exclusion chromatography analysis of antibody drug conjugates using the agilent 1260 infinity ii bioinert lc system.
Largescale manufacturing of pharmaceutical antibodies is a complex activity that requires considerable effort in both process and analytical development. Extremes of ph, ionic strength, temperature, concentration, shear forces, and other processing conditions can lead to increased aggregation. Analysis of monoclonal antibodies and their fragments by size. Antibodydrug conjugates adcs are monoclonal antibodies coupled to cytotoxic agents with stable linkers. After completing this chapter, students will be able to. Antibody aggregation could be triggered by partial unfolding of its domains, leading to monomermonomer. But this method can provide misleading results because aggregates can dissociate or form during sec andor adsorb to the column resin. Aggregation and chemical modification of monoclonal. Aggregates in mab therapeutics pose a risk to patients. Current trends in monoclonal antibody development and manufacturing will provide readers with an understanding of what is currently being done in the industry to develop, manufacture, and release. The control and avoidance of aggregation in the manufacturing process are needed because aggregates affect drug performance and safety97,98. Given the high cell densities achievable in both mammalian cell culture and microbial processes, primary recovery can be a. The stability of 11 purified monoclonal human igg1 and igg4 antibodies, including an igg1based bispecific crossmab, was compared in downscale mixing stress models. It has been more than a decade since the industry started establishing the process platform.
Monoclonal antibodies can have monovalent affinity. Adcs travel to target cells, where the antibody binds to its antigen expressed on the cell surface. Nonsizebased membrane chromatographic separation and. Lang2 1manufacturing science and technology, lonza biologics porrin.
1249 1479 214 116 187 449 295 131 678 380 49 107 133 145 43 1443 389 836 1087 1057 344 916 818 38 1432 1086 1429 44 846 616 1025 311